Geoffrey Beran Rose Sells 7,732 Shares of Pulmonx (NASDAQ:LUNG) Stock

Pulmonx Corporation (NASDAQ:LUNG) insider Geoffrey Beran Rose sold 7,732 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $1.43, for a total transaction of $11,056.76. Following the transaction, the insider owned 365,734 shares in the company, valued at $522,999.62. This represents a 2.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Pulmonx Stock Down 5.9%

LUNG stock traded down $0.09 during trading on Wednesday, reaching $1.44. 579,968 shares of the stock were exchanged, compared to its average volume of 360,844. The firm’s 50 day moving average is $1.79 and its 200 day moving average is $1.79. The company has a quick ratio of 4.15, a current ratio of 4.86 and a debt-to-equity ratio of 0.62. Pulmonx Corporation has a twelve month low of $1.31 and a twelve month high of $8.71.

Analysts Set New Price Targets

A number of research analysts have weighed in on LUNG shares. Wall Street Zen raised shares of Pulmonx from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Pulmonx in a research note on Thursday, January 22nd. Finally, D. Boral Capital restated a “buy” rating and issued a $14.00 target price on shares of Pulmonx in a report on Friday, February 20th. Five equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Pulmonx currently has a consensus rating of “Hold” and a consensus target price of $6.81.

Key Stories Impacting Pulmonx

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Pulmonx closed a five‑year credit facility of up to $60 million with Perceptive Advisors that includes a $40M term loan (with an option for an additional $20M tied to revenue milestones). Management says the financing extends debt maturity to 2031 and strengthens the balance sheet to support commercial and clinical priorities. Article Title
• Positive Sentiment: Q4 results showed improvement vs. a year ago: narrower GAAP loss ($0.25/sh) and adjusted EBITDA loss improved; full‑year 2025 revenue rose to $90.5M (up 8% YoY) and gross margin expanded to ~78% in Q4 — evidence of operating leverage and cost reductions. Article Title
• Neutral Sentiment: Management issued 2026 revenue guidance of $90M–$92M and expects ~75% gross margin with operating expenses $113M–$115M — guidance gives visibility but comes in below some analyst estimates, leaving mixed signals on near‑term topline momentum. Article Title
• Negative Sentiment: Several insiders sold stock on March 2 (including CEO Glendon E. French III, General Counsel David A. Lehman, CCO Geoffrey Beran Rose and Senior staff), representing multiple percent reductions in their holdings — heavy insider selling can pressure sentiment and amplify downside. SEC filings: CEO sale CEO Form 4, Lehman GC Form 4, Beran Rose CCO Form 4, Srikanth Radhakrishnan Form 4
• Negative Sentiment: Q4 U.S. revenue declined (~11% YoY) and total Q4 revenue was down ~5% YoY, signaling softer commercial momentum in Pulmonx’s largest market — the company emphasized a transition plan to reaccelerate U.S. sales, but near‑term growth risk weighed on the stock. Article Title

Institutional Trading of Pulmonx

A number of large investors have recently added to or reduced their stakes in LUNG. Cerity Partners LLC bought a new stake in shares of Pulmonx in the 4th quarter worth approximately $27,000. FNY Investment Advisers LLC purchased a new stake in Pulmonx in the 3rd quarter worth about $29,000. Opal Capital LLC bought a new stake in Pulmonx in the 4th quarter valued at about $29,000. Regatta Capital Group LLC purchased a new stake in Pulmonx during the fourth quarter valued at about $30,000. Finally, Jain Global LLC bought a new position in Pulmonx during the third quarter worth about $30,000. Hedge funds and other institutional investors own 91.04% of the company’s stock.

Pulmonx Company Profile

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.